Literature DB >> 11396228

Expression of endogenous lectins (galectins, receptors for ABH-epitopes) and the MIB-1 antigen in esophageal carcinomas and their syntactic structure analysis in relation to post-surgical tumor stage and lymph node involvement.

K Kayser1, E Hauck, S André, N V Bovin, H Kaltner, L Banach, E Lancaster, H J Gabius.   

Abstract

Squamous cell carcinomas of the esophagus, a disease with poor prognosis, are especially frequent in China and South Africa. To initiate the study of endogenous lectins in this tumor class we employed synthetic neoglycoconjugates and focused on galectins as markers. Histological sections of 43 cases of esophageal carcinomas were analyzed with labeled galectins-1 and -3 and their specific antibodies, neoglycoconjugates exposing chemically prepared histo-blood group A-, B- and H-trisaccharides and the antibody MIB-1 (Ki-67). Features of structural and numerical staining intensities determined quantitatively were correlated to clinical data sets of pTN stages, sex and age of patients. Low tumor stages (pT1/T2) were seen in 10/43 cases (23%) and 65% of the carcinomas surgically treated lacked notable lymph node involvement (pN0). The women were younger than the men (47 years versus 54 years). The proliferation activity of the tumor cells was high and amounted to 75% at average. The presence of galectin-1 and the structural entropy of distribution of staining with carrier-immobilized A-trisaccharide were associated with pN stages. These initial data indicate that distinct glycohistochemical features appear to have prognostic significance in this tumor class, adding to the emerging significance of this marker class in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396228

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 2.  Insight to drug delivery aspects for colorectal cancer.

Authors:  Arvind Gulbake; Aviral Jain; Ashish Jain; Ankit Jain; Sanjay K Jain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

3.  Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer.

Authors:  Wei Wang; Lei Liu; Zhiwei Wang; Min Wei; Qi He; Tianlong Ling; Ziang Cao; Yixin Zhang; Qiang Wang; Minxin Shi
Journal:  BMC Surg       Date:  2015-09-29       Impact factor: 2.102

4.  The Value of ABO Blood Group and Complete Blood Count for the Prognosis Analysis of Gastric Cancer Patients.

Authors:  Xiao-Jie Sun; Le Ai; Yang-Chun Feng
Journal:  Onco Targets Ther       Date:  2020-05-25       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.